AntiCancer, Inc., San Diego, CA, USA.
Cell Cycle. 2011 Aug 15;10(16):2737-41. doi: 10.4161/cc.10.16.16756.
We have previously developed a telomerase-specific replicating adenovirus expressing GFP (OBP-401), which can selectively label tumors in vivo with GFP. Intraperitoneal (i.p.) injection of OBP-401 specifically labeled peritoneal tumors with GFP, enabling fluorescence visualization of the disseminated disease and real-time fluorescence surgical navigation. However, the technical problems with removing all cancer cells still remain, even with fluorescence-guided surgery. In this study, we report imaging of tumor recurrence after fluorescence-guided surgery of tumors labeled in vivo with the telomerase-dependent, GFP-containing adenovirus OBP-401.. Recurrent tumor nodules brightly expressed GFP, indicating that initial OBP-401-GFP labeling of peritoneal disease was genetically stable, such that proliferating residual cancer cells still express GFP. In situ tumor labeling with a genetic reporter has important advantages over antibody and other non-genetic labeling of tumors, since residual disease remains labeled during recurrence and can be further resected under fluorescence guidance.
我们之前开发了一种表达 GFP 的端粒酶特异性复制型腺病毒（OBP-401），它可以在体内选择性地用 GFP 标记肿瘤。腹腔内（i.p.）注射 OBP-401 可以特异性地用 GFP 标记腹膜肿瘤，使播散性疾病的荧光可视化和实时荧光手术导航成为可能。然而，即使进行荧光引导手术，仍存在清除所有癌细胞的技术问题。在这项研究中，我们报告了用端粒酶依赖性、含 GFP 的腺病毒 OBP-401 对体内标记的肿瘤进行荧光引导手术后肿瘤复发的成像。复发性肿瘤结节强烈表达 GFP，表明初始 OBP-401-GFP 标记的腹膜疾病在遗传上是稳定的，因此增殖的残留癌细胞仍然表达 GFP。与抗体和其他非遗传标记肿瘤相比，用遗传报告基因对肿瘤进行原位标记具有重要优势，因为在复发期间残留疾病仍被标记，并且可以在荧光引导下进一步切除。
